APC anti-human CD8 Antibody

Pricing & Availability
Clone
SK1 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Leu2
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
SK1_APC_040810
Human peripheral blood lymphocytes stained with SK1 APC
  • SK1_APC_040810
    Human peripheral blood lymphocytes stained with SK1 APC
Compare all formats See APC spectral data
Cat # Size Price Save
344721 25 tests ¥29,040
344722 100 tests ¥71,500
Description

CD8a is a 32-34 kD type I glycoprotein. It forms a homodimer (CD8a/a) or heterodimer (CD8a/b) with CD8b. CD8, also known as T8 and Leu2, is a member of the immunoglobulin superfamily found on the majority of thymocytes, a subset of peripheral blood T cells, and NK cells (which express almost exclusively CD8a homodimers). CD8 acts as a co-receptor with MHC class I-restricted T cell receptors in antigen recognition and T cell activation and has been shown to play a role in thymic differentiation. Two domains in CD8a are important for function: the extracellular IgSF domain binds the α3 domain of MHC class I and the cytoplasmic CXCP motif binds the tyrosine kinase p56 Lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Chimpanzee, Pigtailed Macaque, Sooty Mangabey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone SK1 recognizes the a chain of CD8. Additional reported applications (for the relevant formats) include: proteogenomics8, immunohistochemistry of acetone-fixed frozen tissue sections, and spatial biology (IBEX)9,10. This clone was tested in-house and does not demonstrate utility for formalin-fixed paraffin-embedded (FFPE) human tonsil sections.

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1981. J. Exp. Med. 153:310.
  2. Campanelli R, et al. 2002. Intl. Immunol. 14:39.
  3. Evans RL, et al. 1981. Immunol. 78:544.
  4. Wooldridge L, et al. 2005. J. Bio. Chem. 280:27491.
  5. Ch'el IL, et al. 2011. J Exp Med. 208:633. PubMed
  6. Carbone A, et al. 1999. Blood 93:2319. (IHC-F)
  7. Ahmed A, et al. 2001. J. Pathol. 193:383. (IHC)
  8. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  9. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  10. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Wu Y, et al. 2021. Cancer Gene Ther. Online ahead of print. PubMed
  2. Qin L, et al. 2022. Sci Adv. 8:eabn3774. PubMed
  3. Tessaro FHG, et al. 2022. Cell Rep. 39:110977. PubMed
  4. Ma T, et al. 2022. Elife. 11: . PubMed
  5. Li K, et al. 2022. Cancer Cell. 40:1374. PubMed
  6. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  7. Kim S, et al. 2023. Front Immunol. 14:1062365. PubMed
  8. Cheng K, et al. 2023. Int J Mol Sci. 24:. PubMed
  9. Tang C, et al. 2023. Nat Commun. 14:1493. PubMed
  10. Li L, et al. 2023. Heliyon. 9:e14219. PubMed
  11. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  12. Wang F, et al. 2018. Oncogenesis. 7:41. PubMed
  13. Tang L, et al. 2021. Oncol Lett. 22:605. PubMed
  14. Wahl S, et al. 2016. Nature. 541:81-86. PubMed
  15. Lugo-Reyes SO, et al. 2021. J Clin Immunol. 41:1291. PubMed
  16. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  17. Zhao L, et al. 2020. Mol Ther Oncolytics. 16:262. PubMed
  18. Kasper M, et al. 2021. Elife. 10:. PubMed
  19. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  20. Reif T, et al. 2021. Cell Reports Medicine. 2(6):100317. PubMed
  21. Kang L, et al. 2020. Exp Hematol Oncol. 9:11. PubMed
  22. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  23. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  24. Kumar A, et al. 2020. Bio Protoc. 10:e3675. PubMed
  25. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  26. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  27. Zou F, et al. 2021. Mol Ther. 29:1794. PubMed
  28. Leitner J, et al. 2015. J Immunol. 195: 477 - 487. PubMed
  29. Jing L, et al. 2020. Cancer Immunol Res. 8:648. PubMed
  30. Thiel BA, et al. 2021. PLoS One. 16:e0249477. PubMed
  31. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  32. Lima J, et al. 2016. Reprod Sci. 10.1177/1933719116653680. PubMed
  33. Wang J, et al. 2019. Oncol Lett. 4.948611111. PubMed
  34. Bear AS, et al. 2021. Nat Commun. 12:4365. PubMed
  35. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  36. Bonte S, et al. 2021. Oncoimmunology. 10:1954800. PubMed
  37. Le J, et al. 2020. Immunity. 52(6):1105-1118.e9. PubMed
  38. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  39. Paul S, et al. 2021. Sci Transl Med. 13:. PubMed
  40. Grant RA, et al. 2021. Nature. 590(7847):635-641. PubMed
  41. Chheda ZS, et al. 2018. J Exp Med. 9:19490. PubMed
  42. Egedal JH, et al. 2021. Mucosal Immunol. 14:1203. PubMed
  43. Roudko V, et al. 2020. Cell. 183(6):1634-1649.e17. PubMed
  44. Su Y, et al. 2020. Cell. 1479:183. PubMed
  45. Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed
  46. Nguyen NT, et al. 2021. Nat Nanotechnol. 16:1424. PubMed
  47. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  48. Loo Yau H, et al. 2021. STAR Protocols. 2(2):100549. PubMed
  49. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  50. Tao L, et al. 2020. Cancers (Basel). 12:00. PubMed
  51. Oliveira A, et al. 2013. Immunology. 140:47. PubMed
  52. Fierle JK, et al. 2021. Cell Reports Medicine. 2(8):100362. PubMed
  53. Hoseini SS, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(5):. PubMed
  54. Walker‐Sperling VE et al. 2017. EBioMedicine. 16:141-149 . PubMed
  55. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  56. Javed A, et al. 2015. PLoS One. 10: 0142086. PubMed
  57. Forsberg EMV, et al. 2019. Cancer Res. 79:899. PubMed
  58. Li B, et al. 2019. Oncogenesis. 8:17. PubMed
  59. Feng Y, et al. 2022. EClinicalMedicine. 43:101226. PubMed
  60. Bhargavan B, et al. 2021. Mol Neurodegener. 16:78. PubMed
RRID
AB_2075388 (BioLegend Cat. No. 344721)
AB_2075388 (BioLegend Cat. No. 344722)

Antigen Details

Structure
Ig superfamily, homodimer or heterodimer with CD8b, 32-34 kD
Distribution

Majority of thymocytes, T cell subset, NK cells

Function
MHC class I co-receptor, thymic differentiation, T cell activation
Ligand/Receptor
MHC Class I molecules
Cell Type
NK cells, T cells, Thymocytes
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay N, et al. 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
925 View all products for this Gene ID
UniProt
View information about CD8 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8 Reagents Request Custom Conjugation
Description Clone Applications
Alexa Fluor® 647 anti-human CD8 SK1 FC
Brilliant Violet 650™ anti-human CD8 SK1 FC
Purified anti-human CD8 SK1 FC,IHC-F
FITC anti-human CD8 SK1 FC
PE anti-human CD8 SK1 FC
PerCP anti-human CD8 SK1 FC
PerCP/Cyanine5.5 anti-human CD8 SK1 FC
PE/Cyanine7 anti-human CD8 SK1 FC
APC/Cyanine7 anti-human CD8 SK1 FC
Alexa Fluor® 488 anti-human CD8 SK1 FC,SB
Pacific Blue™ anti-human CD8 SK1 FC
Biotin anti-human CD8 SK1 FC
APC anti-human CD8 SK1 FC
Alexa Fluor® 700 anti-human CD8 SK1 FC
Purified anti-human CD8 (Maxpar® Ready) SK1 FC,CyTOF®
Brilliant Violet 510™ anti-human CD8 SK1 FC
Brilliant Violet 711™ anti-human CD8 SK1 FC
Brilliant Violet 785™ anti-human CD8 SK1 FC
Brilliant Violet 605™ anti-human CD8 SK1 FC
PE/Dazzle™ 594 anti-human CD8 SK1 FC
PE anti-human CD8 SK1 FC
APC/Fire™ 750 anti-human CD8 SK1 FC
APC anti-human CD8 SK1 FC
Brilliant Violet 421™ anti-human CD8 SK1 FC
Pacific Blue™ anti-human CD8 SK1 FC
TotalSeq™-A0046 anti-human CD8 SK1 PG
TotalSeq™-C0046 anti-human CD8 SK1 PG
Brilliant Violet 750™ anti-human CD8 SK1 FC
TotalSeq™-B0046 anti-human CD8 SK1 PG
Spark Blue™ 550 anti-human CD8 SK1 FC
PE/Cyanine7 anti-human CD8 SK1 FC
FITC anti-human CD8 SK1 FC
APC/Fire™ 810 anti-human CD8 SK1 FC
PE/Fire™ 640 anti-human CD8 SK1 FC
PE/Fire™ 700 anti-human CD8 SK1 FC
PerCP anti-human CD8 SK1 FC
PerCP/Cyanine5.5 anti-human CD8 SK1 FC
TotalSeq™-D0046 anti-human CD8 SK1 PG
APC/Fire™ 750 anti-human CD8 SK1 FC
GMP APC anti-human CD8 SK1 FC
PE/Cyanine5 anti-human CD8 Antibody SK1 FC
Spark UV™ 387 anti-human CD8 SK1 FC
GMP PE anti-human CD8 SK1 FC
GMP PE/Cyanine7 anti-human CD8 SK1 FC
Spark NIR™ 685 anti-human CD8 SK1 FC
KIRAVIA Blue 520™ anti-human CD8 SK1 FC
GMP FITC anti-human CD8 SK1 FC
GMP Pacific Blue™ anti-human CD8 SK1 FC
GMP PerCP anti-human CD8 SK1 FC
Spark Violet™ 500 anti-human CD8 SK1 FC
GMP APC/Fire™ 750 anti-human CD8 SK1 FC
GMP PerCP/Cyanine 5.5 anti-human CD8 SK1 FC
Alexa Fluor® 660 anti-human CD8a SK1 FC
Spark Blue™ 515 anti-human CD8 SK1 FC
Spark Blue™ 574 anti-human CD8 SK1 FC
Spark Violet™ 538 anti-human CD8 SK1 FC
PE/Fire™ 810 anti-human CD8 SK1 FC
Spark YG™ 593 anti-human CD8 SK1 FC

Customers Also Purchased

Go To Top Version: 4    Revision Date: 07/13/2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account